» Articles » PMID: 39337491

Targeting Calcitriol Metabolism in Acute Vitamin D Toxicity-A Comprehensive Review and Clinical Insight

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Sep 28
PMID 39337491
Authors
Affiliations
Soon will be listed here.
Abstract

High-dose vitamin D supplementation is common in the general population, but unsupervised high-dose supplementation in vitamin D-replete individuals poses a risk of severe toxicity. Susceptibility to vitamin D toxicity shows a significant inter-individual variability that may in part be explained by genetic predispositions (i.e., CYP24A1 polymorphism). The classic manifestation of vitamin D toxicity is hypercalcemia, which may be refractory to conventional therapy. Its causes include the endogenous overaction of 1α-hydroxylase, monogenic alterations affecting vitamin D metabolizing enzymes and exogenous vitamin D intoxication. In this manuscript, we include a literature review of potential pharmacological interventions targeting calcitriol metabolism to treat vitamin D intoxication and present a case of severe, exogenous vitamin D intoxication responding to systemic corticosteroids after the failure of conventional therapy. Systemic glucocorticoids alleviate acute hypercalcemia by inhibiting enteric calcium absorption and increasing the degradation of vitamin D metabolites but may cause adverse effects. Inhibitors of 1α-hydroxylase (keto/fluconazole) and inducers of CYP3A4 (rifampicin) may be considered steroid-sparing alternatives for the treatment of vitamin D intoxication.

References
1.
Shultz T, Bollman S, Kumar R . Decreased intestinal calcium absorption in vivo and normal brush border membrane vesicle calcium uptake in cortisol-treated chickens: evidence for dissociation of calcium absorption from brush border vesicle uptake. Proc Natl Acad Sci U S A. 1982; 79(11):3542-6. PMC: 346457. DOI: 10.1073/pnas.79.11.3542. View

2.
Zittermann A, Trummer C, Theiler-Schwetz V, Pilz S . Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2023; 62(4):1833-1844. PMC: 10195747. DOI: 10.1007/s00394-023-03124-w. View

3.
Burton J, Kimball S, Vieth R, Bar-Or A, Dosch H, Cheung R . A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010; 74(23):1852-9. PMC: 2882221. DOI: 10.1212/WNL.0b013e3181e1cec2. View

4.
Walker M, Shane E . Hypercalcemia: A Review. JAMA. 2022; 328(16):1624-1636. DOI: 10.1001/jama.2022.18331. View

5.
Wang J, Shu B, Li C, Xie X, Liang D, Chen B . Polymorphisms of genes related to vitamin D metabolism and transportation and its relationship with the risk of osteoporosis: protocol for a multicentre prospective cohort study in China. BMJ Open. 2019; 9(11):e028084. PMC: 6886991. DOI: 10.1136/bmjopen-2018-028084. View